MTOR and head and neck cancer: In a recent study from patient-derived tumorgrafts of head and neck cancers, Liu et al. revealed that PIK3CA or PIK3R1 mutations could predict sensitivity to the PI3K/mTOR inhibitor BEZ-235 [58].